New-generation incubator brings the latest technology to mid-capacity microplate cell culture
New Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator delivers robust and reliable culture solution for cell-based pharmaceutical applications.
As the pharmaceutical industry continues to increase its focus on the development of biologics, scientists require robust, automation-ready incubation solutions with the reliability and flexibility to support a range of discovery, development and processing applications for future cell-based and cell-derived medicines.
Underpinned by over 50 years of experience in advanced environmental chamber and incubation technology, the Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists in the pharmaceutical industry with an automation-ready, mid-capacity cell culture solution. The new automated incubator system delivers cell growth and environmental control across a range of microplate applications, including cell-based screening, immuno-capture assays, microbiology and enzyme testing. Designed for fast and flexible integration, the Cytomat 2 C-LiN Series Automated Incubator enhances laboratory automation installations.
Thermo Fisher Scientific is showcasing its new generation of automated incubators during the 2019 European conference and exhibition of the Society for Laboratory Automation and Screening (SLAS Europe) being held June 26–28, Booth #418 at the Centre de Convencions Internacional, Barcelona, Spain.
"With the increasing number of biotherapeutics in development and their ever-growing complexity, scientists need cell culture solutions they can trust to deliver dependable cellular growth within a controlled and contamination-free environment," said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific. "The launch of the Cytomat 2 C-LiN Series Automated Incubator brings the latest automation-ready incubation technology to mid-capacity microplate applications, enabling scientists to more easily sustain valuable and vital cell lines for the synthesis and development of future therapeutics."
The Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists with
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance